Drug firms call for changes to German law that limits drug pricesBMJ 2012; 344 doi: http://dx.doi.org/10.1136/bmj.e1489 (Published 28 February 2012) Cite this as: BMJ 2012;344:e1489
- Annette Tuffs
The new law in Germany that fixes the prices of drug according to cost-benefit comparisons with similar drugs is working, says the Institute for Quality and Efficiency in Health Care (IQWIG), the German equivalent of the UK National Institute for Health and Clinical Excellence, after evaluating 10 new drugs on the market.
Three of the drugs offered substantial added value for certain indications and two offered a minor improvement. “This is a much better result than expected,” said Jürgen Windeler, head of IQWIG, in a public statement. Experts expect just one in 20 new drugs to be …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial